Teva Pharmaceutical Industries Ltd said Friday it hoped to win U.S. approval by late 2017 or early 2018 for its version of Mylan NV’s EpiPen device for treating severe allergic reactions, a move that would challenge the branded product’s overwhelming market dominance.
Analysts have predicted that Teva’s product, if approved and priced cheaper than EpiPen, could eat up a significant portion of the branded product’s current 94 percent market share.
Source: Reuters
Filed Under: Drug Discovery
